Quick Answer: Clinically diagnosed gastroparesis in GLP-1 receptor agonist users appears uncommon, though precise incidence rates remain uncertain due to methodologic challenges in distinguishing expected gastric emptying delay from pathologic gastroparesis
Coverage for GLP-1s for weight loss is not required under the federal Employee Retirement Income Security Act (ERISA)
A simple weekly log capturing weight, notable symptoms, medication adherence, and general well-being creates a comprehensive record for clinical discussions
Another retrospective cohort study, which included 543,595 diabetic patients, found no increased risk of pancreatic cancer associated with GLP-1RA use compared to basal insulin over a 9-year follow-up period (Nagendra et al., 2023)
Signs include: Intense cravings for sugar or carbs
Shah, R., Hunt, J., Webb, T